Overview

A Study of LY2835219 in Healthy Participants

Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to compare how much of the study drug gets into the blood stream when it is given as a single oral dose and as an intravenous infusion (given directly into a vein via a small needle). The study will also provide information on how well the study drug is tolerated when given as a capsule in combination with giving it intravenously, and information on any changes in heart function. The study will last about 10 days. Screening is required within 28 days before study drug is given.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company